Moderate evidence suggests that a gonadotropin (Gn)-releasing hormone (GnRH)-antagonist protocol can significantly reduce the incidence of ovarian hyperstimulation syndrome (OHSS) [1–3], and the use of a GnRH-antagonist protocol is gradually being adopted by clinicians. The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.